skip to Main Content

  »  News  »  Presentation of 2022 ISCD Award-Winning Abstract on TBS and Denosumab

At the 2022 ISCD Annual Meeting, our CEO Prof. Didier Hans presented his award-winning abstract on ‘Long-Term Effect of Denosumab on Bone Microarchitecture as Assessed by Tissue Thickness-Adjusted Trabecular Bone Score (TBS) in Postmenopausal Women with Osteoporosis: Results from the Freedom and Open-Label Extension (OLE)’.

Watch the presentation and learn how years of denosumab treatment improved TBS assessment of bone microarchitecture independently of BMD.


Recent News

Back To Top